CYP11a1 inhibitor, preparation method therefor and use thereof

WO2025051216A9PCT designated stage expired Publication Date: 2026-07-16SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
SHENZHEN ZHONGGE BIOLOGICAL TECH CO LTD
Filing Date
2024-09-06
Publication Date
2026-07-16

AI Technical Summary

Technical Problem

Existing treatments are ineffective in inhibiting the CYP11A1 enzyme, leading to disease progression in patients with castration-resistant prostate cancer (CRPC), especially due to the upregulation of enzymes involved in steroid biosynthesis and the persistent activation of steroid hormones such as 11-ketotestosterone.

Method used

A compound of formula (0) has been developed as a CYP11A1 inhibitor that blocks the entire steroid biosynthetic pathway by inhibiting cholesterol side-chain cleavage enzymes, particularly for the treatment of androgen receptor-dependent cancers such as prostate cancer.

Benefits of technology

It effectively inhibits the CYP11A1 enzyme, blocking steroid biosynthesis and potentially treating steroid hormone-dependent diseases, including castration-resistant prostate cancer, especially advanced cancers refractory to existing therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024117298_16072026_PF_FP_ABST
    Figure CN2024117298_16072026_PF_FP_ABST
Patent Text Reader

Abstract

The present application relates to a compound represented by formula (I). The compound can inhibit steroid hormone dependent conditions and diseases of CYP11A1. The present application further comprises a pharmaceutical composition comprising the compound represented by formula (I), and a method for treating a condition related to CYP11A1 activity.
Need to check novelty before this filing date? Find Prior Art